{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:52:42Z","timestamp":1790052762304,"version":"4.0.1"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Liver tumors, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and liver-dominant metastases, remain associated with high mortality despite advances in systemic therapy. Intratumoral therapies have emerged as a promising strategy to achieve high local drug concentrations, modulate the tumor microenvironment, and enhance systemic anti-tumor immunity while limiting systemic toxicity. Although intratumoral approaches have demonstrated clinical success in melanoma, their translation to liver malignancies presents unique biological, immunologic, and technical challenges. This review synthesizes clinical evidence from the past decade evaluating intratumoral therapies for primary and metastatic liver tumors, including oncolytic viruses, cell-based immunotherapies,\n                    <jats:italic>in situ<\/jats:italic>\n                    immunomodulators, intratumoral chemotherapy, and combination strategies with locoregional or systemic treatments. Across early- and late-phase trials, intratumoral therapies have produced heterogeneous outcomes, ranging from tumor necrosis and disease stabilization to occasional systemic (abscopal) responses, while several large studies have failed to demonstrate survival benefit. These mixed results reflect the liver\u2019s highly tolerogenic immune microenvironment, characterized by abundant myeloid-derived suppressor cells, regulatory T cells, and abnormal vasculature that limit immune activation and drug distribution. We highlight key determinants of efficacy, including tumor biology, delivery technique, dosing strategy, and rational therapeutic combinations. Technical considerations such as image-guided injection, intratumoral pressure, and standardization of administration are reviewed, alongside emerging biomarkers, including immune, molecular, and imaging-based markers, that may enable improved patient selection. Overall, current evidence suggests that intratumoral therapies alone are rarely sufficient for liver tumors but may provide meaningful benefit when integrated into multimodal regimens. Future progress will depend on optimized combination strategies, standardized delivery approaches, and validated biomarkers to support personalized application in liver cancer.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1726128","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:34:49Z","timestamp":1770183289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Advancements in intratumoral therapies for liver tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Steven S.","family":"Raman","sequence":"first","affiliation":[{"name":"Radiology, Department of Radiological Sciences Director, University of California, Los Angeles (UCLA) Uterine Fibroid Program, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]},{"name":"Abdominal Imaging Fellowship Program, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal R.","family":"Cutler","sequence":"additional","affiliation":[{"name":"Concierge Clinical Trials","place":["Beverly Hills, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Sramek","sequence":"additional","affiliation":[{"name":"Clinical Research, Concierge Clinical Trials","place":["Beverly Hills, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Randolph","family":"Hecht","sequence":"additional","affiliation":[{"name":"Clinical Medicine, David Geffen School of Medicine at UCLA","place":["Los Angeles, CA, United States"]},{"name":"University of California, Los Angeles Gastrointestinal Oncology Program, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]},{"name":"Department of Surgery, Dumont-University of California, Los Angeles Liver Cancer Center, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]},{"name":"Signal Transduction and Therapeutics, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth R.","family":"Anand","sequence":"additional","affiliation":[{"name":"Signal Transduction and Therapeutics, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]},{"name":"Department of Medicine - Hematology\/Oncology, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chiang","sequence":"additional","affiliation":[{"name":"Abdominal Imaging and Interventional Radiology, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Lu","sequence":"additional","affiliation":[{"name":"Radiology and Surgery, Abdominal Imaging and Intervention Director, Computed Tomography, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]},{"name":"Interventional Oncology, University of California, Los Angeles (UCLA) Healthcare","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7150\/jca.76809","article-title":"Six cell cycle-related genes serve as potential prognostic biomarkers and correlated with immune infiltrates in hepatocellular carcinoma","volume":"14","author":"Shi","year":"2023","journal-title":"J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/15384047.2020.1804284","article-title":"Epigenetic age acceleration of early stage hepatocellular carcinoma tightly associated with hepatitis B virus load, immunoactivation, and improved survival","volume":"21","author":"Fan","year":"2020","journal-title":"Cancer Biol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-24-165","article-title":"Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2020.09.002","article-title":"Surgical management of colorectal cancer liver metastases","volume":"30","author":"Padmanabhan","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00353-4","article-title":"Survival improvement for patients with metastatic colorectal cancer over twenty years","volume":"7","author":"Zeineddine","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00660-0","article-title":"Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial","volume":"26","author":"van der Lei","year":"2025","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.36401\/JIPO-22-8","article-title":"The contemporary landscape and future directions of intratumoral immunotherapy","volume":"6","author":"Brito-Orama","year":"2023","journal-title":"J Immunother Precis Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4169-5","article-title":"Phase 2 study of intralesional PV-10 in refractory metastatic melanoma","volume":"22","author":"Thompson","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10453","article-title":"A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma","volume":"7","author":"Ray","year":"2016","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-025-01684-0","article-title":"State-of-the-art in metastatic uveal melanoma treatment: a 2025 update","volume":"27","author":"Ziogas","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Vareki","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad052","article-title":"Intratumoral injection therapies for locally advanced pancreatic cancer: systematic review","volume":"7","author":"Willink","year":"2023","journal-title":"BJS Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100634","article-title":"Initial safety and feasibility results from a phase I, diagnose-and-treat trial of neoadjuvant intratumoral cisplatin for stage IV NSCLC","volume":"5","author":"Khan","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","article-title":"A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus HF10 for unresectable locally advanced pancreatic cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5927","article-title":"Intratumoral injection of mRNA-2752 and pembrolizumab for high-risk ductal carcinoma in situ: a phase I nonrandomized clinical trial","volume":"11","author":"Ramalingam","year":"2025","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","article-title":"Preliminary results of the first-in-human study of MK-1454 as monotherapy or in combination with pembrolizumab in patients with solid tumors or lymphomas [abstract","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2824","article-title":"Intratumoral or subcutaneous MK-2118, a noncyclic dinucleotide STING agonist, with or without pembrolizumab, for advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Luke","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1633315","article-title":"Immune microenvironment regulation and clinical immunotherapy strategies of metastatic liver cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460282","article-title":"Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12935-021-01972-2","article-title":"Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12672-023-00681-8","article-title":"The role of myeloid-derived suppressor cells in liver cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Discov Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00387","article-title":"The role of myeloid-derived suppressor cells in immune ontogeny","volume":"5","author":"Gantt","year":"2014","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.23054","article-title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor","volume":"50","author":"Hoechst","year":"2009","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-25-0251","article-title":"Myeloid-derived suppressor cells: orchestrators of tumor immune evasion and therapeutic vulnerabilities","volume":"23","author":"Wang","year":"2025","journal-title":"Mol Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0225327","DOI":"10.1371\/journal.pone.0225327","article-title":"The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2019","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075043","article-title":"Induced CD4+Foxp3+ regulatory T cells in immune tolerance","volume":"30","author":"Bilate","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e95009","DOI":"10.7554\/eLife.95009","article-title":"Exploring the role of\u00a0the\u00a0immune microenvironment in hepatocellular carcinoma: implications for\u00a0immunotherapy and drug resistance","volume":"13","author":"Fu","year":"2024","journal-title":"eLife"},{"key":"B37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12967-025-06124-y","article-title":"High interstitial fluid pressure enhances USP1-dependent KIF11 protein stability to promote hepatocellular carcinoma progression","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.02.010","article-title":"Reengineering the tumor vasculature: improving drug delivery and efficacy","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1655794","article-title":"Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models","volume":"15","author":"Cournoyer","year":"2025","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114505","article-title":"Image-guided intratumoral immunotherapy: developing a clinically practical technology","volume":"189","author":"Som","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581098","article-title":"Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances","volume":"16","author":"Xie","year":"2025","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102381","article-title":"Immunotherapy and microbiota for targeting of liver\u00a0tumor-initiating stem-like cells","volume":"14","author":"Machida","year":"2022","journal-title":"Cancers"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e91980","DOI":"10.1172\/jci.insight.91980","article-title":"Intestinal barrier regulates immune responses in the liver via IL-10-producing macrophages","volume":"3","author":"Taniki","year":"2018","journal-title":"JCI Insight"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658795","article-title":"Progress in targeting tumor-associated macrophages in cancer immunotherapy","volume":"16","author":"Xia","year":"2025","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100741","article-title":"Tumor-associated macrophages: polarization, immunoregulation, and immunotherapy","volume":"14","author":"Saeed","year":"2025","journal-title":"Cells"},{"key":"B46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduction Targeting Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e20230053","DOI":"10.1084\/jem.20230053","article-title":"An oncolytic virus-delivered TGF\u03b2 inhibitor overcomes the immunosuppressive tumor microenvironment","volume":"220","author":"DePeaux","year":"2023","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490414","article-title":"Neutrophils in oncolytic virus immunotherapy","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e004167","DOI":"10.1136\/jitc-2022-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040706","article-title":"DC-based vaccines for cancer immunotherapy","volume":"8","author":"Fu","year":"2020","journal-title":"Vaccines"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2096363","article-title":"Trial watch: dendritic cell (DC)-based immunotherapy for cancer","volume":"11","author":"Laureano","year":"2022","journal-title":"OncoImmunology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure \u2013 an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12964-021-00796-x","article-title":"Drug delivery strategy in hepatocellular carcinoma therapy","volume":"20","author":"Yang","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.21037\/tgh-23-11","article-title":"Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers","volume":"8","author":"Sankar","year":"2023","journal-title":"Transl Gastroenterol Hepatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40364-025-00774-2","article-title":"The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma","volume":"13","author":"Guo","year":"2025","journal-title":"biomark Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"19583","DOI":"10.1038\/s41598-024-68048-9","article-title":"NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma","volume":"14","author":"Du","year":"2024","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100672","article-title":"High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma","volume":"5","author":"Yang","year":"2023","journal-title":"JHEP Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101130","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"6","author":"Childs","year":"2024","journal-title":"JHEP Rep"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open-label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1159\/000528034","article-title":"Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study","volume":"12","author":"Xu","year":"2022","journal-title":"Liver Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40644-024-00763-y","article-title":"Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations","volume":"24","author":"Bitar","year":"2024","journal-title":"Cancer Imaging"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15202641","article-title":"Navigating biopsy safety: complication rates under ultrasound and CT guidance","volume":"15","author":"Patzer","year":"2025","journal-title":"Diagnostics"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2017.18.2.309","article-title":"Ultrasound-guided percutaneous core needle biopsy of abdominal viscera: tips to ensure safe and effective biopsy","volume":"18","author":"Kim","year":"2017","journal-title":"Korean J Radiol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17998\/jlc.2025.02.16","article-title":"Recent advances and issues in imaging modalities for hepatocellular carcinoma surveillance","volume":"25","author":"Lee","year":"2025","journal-title":"J Liver Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.22575\/interventionalradiology.2023-0047","article-title":"Basic techniques and technical tips for ultrasound-guided needle puncture","volume":"9","author":"Sato","year":"2024","journal-title":"Interv Radiol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00450","article-title":"Theranostics in interventional oncology: versatile carriers for diagnosis and targeted image-guided minimally invasive procedures","volume":"10","author":"Degrauwe","year":"2019","journal-title":"Front Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v13.i10.314","article-title":"Current trends and perspectives in interventional radiology for gastrointestinal cancers","volume":"13","author":"Reitano","year":"2021","journal-title":"World J Radiol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.666020","article-title":"Infant and child MRI: a review of scanning procedures","volume":"15","author":"Copeland","year":"2021","journal-title":"Front Neurosci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1630424","article-title":"MRI management of focal liver lesions: what a beginner cannot fail to know","volume":"15","author":"Granata","year":"2025","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.22575\/interventionalradiology.2023-0033","article-title":"Magnetic resonance imaging guidance for percutaneous needle intervention","volume":"9","author":"Uka","year":"2023","journal-title":"Interv Radiol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15131573","article-title":"Real-life clinical use and outcomes of fusion imaging-guided percutaneous microwave ablation of hepatocellular carcinoma: experience from two Italian centers","volume":"15","author":"Biondetti","year":"2025","journal-title":"Diagnostics"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000368001","article-title":"Ultrasound fusion imaging of hepatocellular carcinoma: a review of current evidence","volume":"32","author":"Minami","year":"2014","journal-title":"Dig Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e38673","DOI":"10.1097\/MD.0000000000038673","article-title":"Ultrasound-guided percutaneous liver biopsy: a review of what operators need to know","volume":"103","author":"Alturkistani","year":"2024","journal-title":"Medicine"},{"key":"B83","doi-asserted-by":"publisher","first-page":"99","DOI":"10.17998\/jlc.20.2.99","article-title":"Imaging modalities for hepatocellular carcinoma surveillance: expanding horizons beyond ultrasound","volume":"20","author":"Park","year":"2020","journal-title":"J Liver Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1089","article-title":"Computed tomography versus magnetic resonance imaging for hepatic lesion characterization and diagnosis","volume":"17","author":"Elbanna","year":"2021","journal-title":"Clin Liver Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030409","article-title":"A comparison of the efficacy and safety of US-, CT-, and MR-guided radiofrequency and microwave ablation for HCC: a systematic review and network meta-analysis","volume":"17","author":"Li","year":"2025","journal-title":"Cancers"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1564705","article-title":"Navigational tools for interventional radiology and interventional oncology applications","volume":"32","author":"Chehab","year":"2015","journal-title":"Semin Interv Radiol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15141754","article-title":"Overall survival and complication rates in the treatment of liver carcinoma: a comparative study of ultrasound, computed tomography, and combined ultrasound and computed tomography guidance for radiofrequency ablation","volume":"15","author":"Chien","year":"2025","journal-title":"Diagnostics"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/160867","article-title":"Interventional radiology and the care of the oncology patient","volume":"2011","author":"O\u2019Neill","year":"2011","journal-title":"Radiol Res Pract"},{"key":"B89","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jvir.2016.01.010","article-title":"CT-guided percutaneous microwave ablation of tumors in the hepatic dome: assessment of efficacy and safety","volume":"27","author":"Asvadi","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1159\/000533650","article-title":"PHOCUS: A phase 3, randomized, open-label study of sequential treatment with pexa-vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma","volume":"13","author":"Abou-Alfa","year":"2023","journal-title":"Liver Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.04.006","article-title":"Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: phase I clinical trial","volume":"31","author":"Heo","year":"2023","journal-title":"Mol Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1605177","article-title":"Oncolytic virus VG161 offers new hope for refractory liver cancer","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00019","article-title":"Phase I trial with the cell-based immune primer ilixadencel, alone, and combined with sorafenib, in advanced hepatocellular carcinoma","volume":"9","author":"Rizell","year":"2019","journal-title":"Front Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/ijc.IJC_635_18","article-title":"Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma","volume":"58","author":"Song","year":"2021","journal-title":"Indian J Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100777","article-title":"Safety and long-term outcome of intratumoral injection of OK432-stimulated dendritic cells for hepatocellular carcinomas after radiofrequency ablation","volume":"13","author":"Kitahara","year":"2020","journal-title":"Transl Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04246.x","article-title":"Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization","volume":"163","author":"Nakamoto","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.0653","article-title":"Phase I\/II clinical trial for radiation and dendritic cell combination immunotherapy in patients with unresectable hepatocellular carcinoma and cholangiocarcinoma","volume":"12","author":"Wu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164178","article-title":"Oncolytic viruses and immune checkpoint inhibitors: the \u201chot\u201d new power couple","volume":"15","author":"Lovatt","year":"2023","journal-title":"Cancers"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102239","article-title":"The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study","volume":"9","author":"Yi","year":"2024","journal-title":"ESMO Open"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S520710","article-title":"In situ vaccination with Poly-ICLC combined with systemic nivolumab for the treatment of unresectable hepatocellular carcinoma","volume":"12","author":"Liang","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100884","article-title":"Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","volume":"8","author":"Hecht","year":"2023","journal-title":"ESMO Open"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae203","article-title":"Phase Ib\/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma","volume":"30","author":"Hecht","year":"2025","journal-title":"Oncologist"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e002224","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1078-0432.CCR-20-2065","article-title":"Intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors","volume":"27","author":"Janku","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2023.08.004","article-title":"Combination treatment of intratumoral vidutolimod, radiosurgery, nivolumab, and ipilimumab for microsatellite stable colorectal carcinoma with liver metastases","volume":"22","author":"Margalit","year":"2023","journal-title":"Clin Colorectal Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"xi45","DOI":"10.1093\/annonc\/mdz451.032","article-title":"A Phase I study of percutaneous oncolytic Rose Bengal disodium for metastatic uveal melanoma patients with hepatic metastases: a single-center cohort summary","volume":"30","author":"Patel","year":"2019","journal-title":"Ann Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","article-title":"Armed oncolytic viruses: a kick-start for anti-tumor immunity","volume":"41","author":"de Graaf","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47110878","article-title":"Recombinant oncolytic viruses: hexagonal warriors in the field of solid tumor immunotherapy","volume":"47","author":"Zhang","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e008025","DOI":"10.1136\/jitc-2023-008025","article-title":"Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor\u2013glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061808","article-title":"Adoptive cell therapy in hepatocellular carcinoma: a review of clinical trials","volume":"15","author":"Ozer","year":"2023","journal-title":"Cancers"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S222097","article-title":"Intratumoral IL-12 gene therapy inhibits tumor growth in a HCC-Hu-PBL-NOD\/SCID murine model","volume":"12","author":"Zhou","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e1477459","DOI":"10.1080\/2162402X.2018.1477459","article-title":"Combination of radiation and interleukin-12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of the tumor microenvironment","volume":"7","author":"Wu","year":"2018","journal-title":"OncoImmunology"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Dongye","year":"2022","journal-title":"Br J Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral immunotherapy\u2014update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0473","article-title":"Intratumoral immunotherapy: from trial design to clinical practice","volume":"27","author":"Champiat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031098","article-title":"Talimogene laherparepvec (T-VEC): a review of the recent advances in cancer therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"J Clin Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/bs.acr.2022.03.002","article-title":"Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: current and developing strategies","volume":"156","author":"Argemi","year":"2022","journal-title":"Adv Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/hbsn.2016.11.04","article-title":"Pathology of intrahepatic cholangiocarcinoma","volume":"6","author":"Vijgen","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216799","article-title":"Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"588","author":"Jiang","year":"2024","journal-title":"Cancer Lett"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203542","article-title":"Tumor immune microenvironment in intrahepatic cholangiocarcinoma: regulatory mechanisms, functions, and therapeutic implications","volume":"16","author":"Ricci","year":"2024","journal-title":"Cancers"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i32.4614","article-title":"Locoregional treatments for hepatocellular carcinoma: current evidence and future directions","volume":"25","author":"Inchingolo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20517\/2394-5079.2021.140","article-title":"Tumor microenvironment and immunology of cholangiocarcinoma","volume":"8","author":"Cadamuro","year":"2022","journal-title":"Hepatoma Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205151","article-title":"R1 vascular or parenchymal margins: what is the impact after resection of intrahepatic cholangiocarcinoma","volume":"14","author":"Mabilia","year":"2022","journal-title":"Cancers"},{"key":"B128","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/hbsn.2016.11.02","article-title":"Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects","volume":"6","author":"Savic","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with tumor ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2016","journal-title":"J Hepatol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e001800","DOI":"10.1136\/jitc-2020-001800","article-title":"Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy","volume":"9","author":"Mu\u00f1oz","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e008378","DOI":"10.1136\/jitc-2023-008378","article-title":"Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease","volume":"12","author":"Luke","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1091088","article-title":"Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma","volume":"12","author":"Peng","year":"2023","journal-title":"Front Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S522136","article-title":"Advances in multimodal imaging\u00a0techniques for evaluating and predicting the efficacy of immunotherapy for non-small cell lung cancer","volume":"17","author":"Liu","year":"2025","journal-title":"Cancer Manage Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268289","article-title":"Approaches to imaging immune activation using PET","volume":"66","author":"Parihar","year":"2025","journal-title":"J Nucl Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ctro.2021.03.006","article-title":"Radiomic biomarkers of tumor immune biology and immunotherapy response","volume":"28","author":"Wang","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11111717","article-title":"Immunotherapeutic agents for\u00a0intratumoral immunotherapy","volume":"11","author":"Shyr","year":"2023","journal-title":"Vaccines"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1726128\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:31:10Z","timestamp":1771925470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1726128\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":137,"alternative-id":["10.3389\/fonc.2026.1726128"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1726128","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1726128"}}